Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2013.11.001PMID 24289901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

  2016cited by this paper
• Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics

  2014cited by this paper
• Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).

  2013cited by this paper
• Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Cancer Incidence in Five Continents Vol. X

  2013cited by this paper
• Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

  2013cited by this paper
• Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

  2013cited by this paper
• Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.

  2013cited by this paper
• Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

  2013cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012influential reference
• Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.

  2012cited by this paper
• A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

  2012cited by this paper
• Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

  2012cited by this paper
• Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100.

  2012cited by this paper
• Trends in prostate cancer in the United States.

  2012cited by this paper
• Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.

  2012cited by this paper
• Survival in metastatic castration resistant prostate cancer (mCRPC) trial participants.

  2012cited by this paper
• Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study

  2012cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

  2012cited by this paper
• Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

  2012cited by this paper
• Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

  2012cited by this paper
• Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).

  2012cited by this paper
• The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer

  2012cited by this paper
• Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

  2012cited by this paper
• Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

  2012cited by this paper
• Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

  2012cited by this paper
• [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

  2011cited by this paper
• Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

  2011cited by this paper
• Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

  2011influential reference
• Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• 前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療

  2011cited by this paper
• Cancer and Leukemia Group B

  2010cited by this paper
• Prostate cancer screening in a Saudi population: an explanatory trial study

  2010cited by this paper
• Cancer incidence in Jordan, 1996-2005.

  2010cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• CANCER EPIDEMIOLOGY IN LEBANON

  2010influential reference
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

  2009cited by this paper
• [EAU guidelines on prostate cancer].

  2009cited by this paper
• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

  2009cited by this paper
• Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer

  2009cited by this paper
• A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

  2008cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

  2007cited by this paper
• The incidence of prostate cancer in Iran: results of a population-based cancer registry.

  2007cited by this paper
• A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

  2007cited by this paper
• Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

  2007cited by this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cited by this paper
• EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

  2006cited by this paper
• Prostate cancer epidemiology.

  2006cited by this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cited by this paper
• Risk models for predicting chemotherapy-induced neutropenia.

  2005cited by this paper
• A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.

  2005cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004influential reference
• Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998.

  2004cited by this paper
• Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004influential reference
• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

  2004cited by this paper
• The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.

  2003cited by this paper
• Prostate cancer epidemiology.

  2003cited by this paper
• Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

  2003cited by this paper
• Epidemiology of febrile neutropenia.

  2003cited by this paper
• Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.

  2003cited by this paper
• A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

  2003cited by this paper
• Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.

  2003cited by this paper
• Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

  2002cited by this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002cited by this paper
• Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.

  2001cited by this paper
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  2001cited by this paper
• Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.

  2001cited by this paper
• Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

  2001cited by this paper
• EAU Guidelines on Prostate Cancer

  2001cited by this paper
• Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

  2001cited by this paper
• Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.

  2001cited by this paper
• Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

  2001cited by this paper
• Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

  2001cited by this paper
• Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

  2001cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.

  1999cited by this paper
• A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.

  1999cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.

  1996cited by this paper

• Message from the chief executive officer

  2025cites this paper
• THE ROLE OF DOCETAXEL AS FIRST-LINE CHEMOTHERAPY ON PSA LEVEL AND QOL IN CRPC PATIENTS

  2024cites this paper
• Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations

  2019cites this paper
• Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.

  2017cites this paper
• Determinants of Behavioral Intentions to Screen for Prostate Cancer in Omani Men

  2017influential citation
• EGF like domain multiple 7 regulates the migration and invasion of prostate cancer cells

  2017cites this paper
• The use of cheminformatics methods for predicting adverse drug responses by human androgen receptor

  2016cites this paper